Pilot2Service Spin-out vs. Licensing Pathway
Purpose
Choose the right commercialisation pathway for a research result: spin-out (equity-based), licensing (royalty-based), or hybrid.
Based on
the owner's published commercialisation guide (owner, 2025). Chapters "Commercialisation Pathways" and "Hybrid and Other Models" (pp. 20-23).
- Spin-out: control and upward-scaling return, but a long and expensive pathway.
- Licensing: a faster pathway, leverages the licensee's existing channels, but a smaller upside.
- Trend: large players (e.g. pharma) increasingly acquire a proven spin-out rather than licensing raw university IP.
Method
- List the pros/cons of both pathways for your own case: control vs. speed, risk vs. available resources.
- Assess the nature of the technology: a platform technology with broad applications favours a spin-out; a narrow improvement to a mature product favours licensing.
- Assess the team's willingness to commit — is someone prepared to build a company for years, or is the goal royalty income and seeing the product on the market without entrepreneurship?
- Assess industry dynamics: e.g. in pharma, large players often acquire a proven spin-out later rather than licensing early-stage IP.
- Consider a hybrid: spin-out plus partial out-licensing later, or a joint venture with an industry partner.
- Keep the pathway flexible — many successful cases change direction (e.g. a spin-out that doesn't secure funding pivots to licensing, or vice versa).
- Involve the TTO in the assessment early — it can see whether the invention has the makings of a VC-fundable venture or is better suited to licensing.
Gotchas
- Step 3 (the team's willingness to commit) is often answered aspirationally under the pull of step 2's platform-technology logic — a founder who says yes to "build a company for years" without that being genuinely true sets up the costly pivot-to-licensing scenario step 6 is meant to absorb, at a higher cost than choosing licensing upfront.
- Step 4's industry dynamics (e.g. pharma increasingly acquiring proven
spin-outs rather than licensing raw IP) are sector-specific — applying
the pharma pattern to a software or deep-tech case without checking
industry-specific-commercialisation-playbookfirst can bias the choice toward "spin-out then get acquired" in a sector where that trend doesn't hold. - Step 2's "platform vs. narrow" framing is a heuristic, not a determinate rule — a narrow-seeming improvement can still favour spin-out if steps 3-4 (commitment, industry dynamics) point that way; don't let step 2 decide alone before the later steps are actually answered.
- This skill's output is explicitly not the legal/financial decision (see "does NOT do") — presenting its pros/cons list to a TTO or investor as the final answer, rather than as an input to that negotiation, skips the step where actual licence terms and university policy get checked.
- Step 7 (involve the TTO early) only works if it happens before a
pathway is informally committed to elsewhere — e.g. telling an industry
partner (per
industry-partner-engagement) "we're spinning out" before the TTO has weighed in removes its ability to correct course cheaply.
What this skill does NOT do
- Does not make the legal or financial decision for you.
- Does not assess a specific licence agreement clause by clause — see
sopimukset:sopimuksen-tarkistusif available. - Does not address your own university's/organisation's exact terms — these vary, check with your TTO.
Continue from here
- Next in this pack:
../ip-disclosure-and-ownership-check/SKILL.md— Establish who owns the IP arising from a research result and make a timely invention disclosure before public disclosure. - Pack's shared guardrails:
../../CLAUDE.md - Overview of the full journey:
../commercialisation-journey-roadmap/SKILL.md
References
../../references/case-studies.md— 7 spin-out examples from different industries and regions../../references/terminology.md— the handbook's glossary../../references/sources.md— the handbook's own source references../../CLAUDE.md— the pack's shared guardrails